Halozyme price target raised to $68 from $55 at Benchmark

Benchmark analyst Robert Wasserman raised the firm’s price target on Halozyme (HALO) to $68 from $55 and keeps a Buy rating on the shares on growing earnings momentum as well as anticipation of pending U.S. approval of Argenx’s (ARGX) subcutaneous Vyvgart for generalized Myasthenia Gravis, or gMG.